Metastatic Colorectal Cancer Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Pfizer, Sanofi, Taiho Pharma, Ono Pharma, Hutchison Medipharma, Isofol Medical, Sumitomo Dainippon Pharma

DelveInsight's "Metastatic Colorectal Cancer Market Insight, Epidemiology And Market Forecast - 2034′′ report offers an in-depth understanding of the Metastatic Colorectal Cancer, historical and forecasted epidemiology as well as the Metastatic Colorectal Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Discover which therapies are expected to grab the Metastatic Colorectal Cancer Market Share @ Metastatic Colorectal Cancer Market Outlook- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Metastatic Colorectal Cancer Market Report
• In April 2025, Buzzard Pharmaceuticals announced a study will enroll patients with colorectal cancer that is locally advanced or metastatic. The tumor must be microsatellite stable (MSS), have a tumor mutational burden that is high (TMB-H) and be kras mutated. Patients must have been treated with available approved treatments already. In this study the investigators are testing a new type of immunotherapy, the potent IL-1 inhibitor isunakinra to be added to already approved immunotherapy (PD-1/PD-L1 inhibitor) in an attempt to get this treatment to work in this treatment resistant type of tumor.
• In April 2025, Mirror Biologics Inc. conducted a study targets the population of mCRC patients that have progressed after two lines of chemotherapy and are not eligible for targeted therapies. The study will assess six different dosing schedules. A standard 3 plus 3 study design will be used. The starting frequency for each dosing schedule will be escalated in subsequent groups of patients. The study will evaluate safety of increased frequency of AlloStim® dosing and anti-tumor effect of the new proposed dose and frequency schedule.
• In April 2025, AbbVie announced a study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combination with oxaliplatin, fluorouracil (5FU), leucovorin (LV) (FOLFOX), and bevacizumab or panitumumab.
• The total incident cases of mCRC in the US were around 79,000 cases in 2024.
• In 2024, Gender-specific cases of CRC in the United States were around 85,000 and 67,000 for male and female, respectively.
• In 2024, the US recorded a higher Incidence of CRC cases in the 65-84 years age group, with approximately 68,000 cases, followed by the 45-64 years age group, which accounted for approximately 57,500 cases.
• In 2024, the United States reported the highest number of cases of CRC in the right colon followed by Left colon, Transverse, cases.
• Germany had the highest incidence of mCRC among the EU4 and the UK, accounting for more than 33,000 cases in 2024.
• In 2024, the total treated cases of mCRC in the US were around 75,000 for the first line, followed by the second line with 49,000 cases.
• The leading Metastatic Colorectal Cancer Companies such as Pfizer, Sanofi, Taiho Pharma, Ono Pharma, Hutchison Medipharma, Isofol Medical, Sumitomo Dainippon Pharma, G1 Therapeutics, Merck, AB Science, Pfizer, Daiichi Sankyo/Astrazeneca, Merck/Eisai, Mirati Therapeutics, Merck, Cardiff Oncology, and others.
• Promising Metastatic Colorectal Cancer Pipeline Therapies such as Adagrasib (MRTX849) + cetuximab, MK-4280A (favezelimab and pembrolizumab), Lynparza (olaparib) ± bevacizumab, Elunate (fruquintinib/HMPL-013), Corsela (trilaciclib), Lenvima (lenvatinib/MK-7902/E7080) + Keytruda (pembrolizumab), Modufolin (arfolitixorin), Lumakras (sotorasib) + Vectibix (panitumumab), Masitinib, Numidargistat (INCB001158), Enhertu (trastuzumab deruxtecan), Keytruda (pembrolizumab) + ibrutinib, Onvansertib, RRx-001, Lenvima (lenvatinib) + pembrolizumab, Tukysa (tucatinib) ± Herceptin (trastuzumab), NT-17/GX-I7 (efineptakin Alfa) + Keytruda (pembrolizumab), BDTX-189, Magrolimab + Erbitux (cetuximab), ONCOS-102 + IMFINZI (durvalumab), and others

Stay ahead in the Metastatic Colorectal Cancer Therapeutics Market with DelveInsight's Strategic Report @ Metastatic Colorectal Cancer Market Outlook- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Metastatic Colorectal Cancer Epidemiology Segmentation in the 7MM
• Total Metastatic Colorectal Cancer Incident cases
• Metastatic Colorectal Cancer Gender-specific cases
• Metastatic Colorectal Cancer Age-specific cases
• Metastatic Colorectal Cancer Tumor location-specific cases
• Metastatic Colorectal Cancer Stage-specific cases
• Total Metastatic Colorectal Cancer Incident cases
• Metastatic Colorectal Cancer Mutation Type-specific cases
• Total Metastatic Colorectal Cancer Treated cases by line of therapy

Download the report to understand which factors are driving Metastatic Colorectal Cancer Epidemiology trends @ Metastatic Colorectal Cancer Prevalence- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Metastatic Colorectal Cancer Marketed Therapies
• FRUZAQLA (fruquintinib): Takeda Pharmaceuticals
FRUZAQLA (fruquintinib) is an oral, once-a-day capsule developed by Takeda Pharms. It is a kinase inhibitor approved for the treatment of adult patients with metastatic Colorectal Cancer (mCRC) who have previously received fluoropyrimidine-, oxaliplatin-, irinotecan-based chemotherapy, an anti-VEGF therapy, and, if appropriate, an anti-EGFR therapy for RAS wild-type patients. It works by selectively inhibiting Vascular Endothelial Growth Factor Receptor (VEGFR)-1, -2, and -3, blocking VEGF-induced endothelial cell proliferation and tumor growth.

• OPDIVO QVANTIG (nivolumab and hyaluronidase-nvhy): Bristol Myers Squibb
OPDIVO QVANTIG (nivolumab and hyaluronidase-nvhy) injection is a treatment for adult patients with MSI-H or dMMR mCRC that has progressed after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, either as monotherapy or following combination treatment with intravenous nivolumab and ipilimumab. It works by binding to the PD-1 receptor, blocking its interaction with PD-L1 and PD-L2.

Metastatic Colorectal Cancer Emerging Therapies
• RYBREVANT (amivantamab) + Chemotherapy: Johnson & Johnson Innovative Medicine
Amivantamab is a bispecific antibody that exhibits specific genetic mutations, particularly EGFR exon 20 insertion mutations. Its mechanism of action involves dual targeting of the epidermal Growth Factor Receptor (eGFR) and the MET receptor, which are critical in tumor growth and survival. By binding to these receptors, amivantamab disrupts their signaling pathways, effectively overcoming certain resistance mechanisms that tumors may develop against other therapies.

• Zanzalintinib (XL092): Exelixis
Zanzalintinib (XL-092) is a third-generation oral tyrosine kinase inhibitor that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL, and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and resistance to multiple therapies, including immune checkpoint inhibitors.

To learn more about Metastatic Colorectal Cancer Treatment guidelines, visit @ Metastatic Colorectal Cancer Treatment Market Landscape- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Metastatic Colorectal Cancer Market Outlook
The metastatic colorectal cancer (mCRC) treatment landscape has evolved significantly, with multiple targeted therapies, immunotherapies, and novel agents expanding beyond traditional chemotherapy. First-line treatment relies on multiagent chemotherapy regimens like FOLFOX, FOLFIRI, and CAPEOX, often combined with anti-angiogenesis or EGFR inhibitors such as bevacizumab, cetuximab, and panitumumab, depending on molecular profiling. Recent approvals have introduced precision medicines like FRUZAQLA, KRAZATI, and LUMAKRAS, addressing specific genetic mutations such as KRAS G12C and BRAF V600E, while immunotherapies like KEYTRUDA, OPDIVO, and JEMPERLI continue to shape the MSI-H/dMMR treatment space. However, despite these advancements, the market remains highly competitive, with significant unmet needs for durable and long-term treatment responses.

Metastatic Colorectal Cancer Market Strengths
• The growing approval of targeted therapies like Lumakras (sotorasib) and immunotherapies such as Keytruda (pembrolizumab) has revolutionized treatment options for mCRC, providing personalized and more effective treatment approaches, which enhance patient outcomes and survival rates.
• The shift toward precision medicine, driven by genetic testing and biomarkers, allows for more accurate identification of suitable treatments based on individual tumor profiles. This has led to improved treatment responses and a more tailored therapeutic approach for patients with mCRC.

Metastatic Colorectal Cancer Market Opportunities
• With the ongoing development of novel therapies like Adagrasib (MRTX849) + cetuximab, and combination treatments (e.g., Lenvima + Keytruda), there is significant potential for improving treatment efficacy and extending survival in mCRC patients, creating a lucrative opportunity for pharmaceutical companies.
• The approval of tumor-agnostic therapies such as Enhertu (trastuzumab deruxtecan) for HER2-positive tumors opens up new avenues for treatment in colorectal cancer and other solid tumors, representing a major growth opportunity in the mCRC market.

Learn more about the FDA-approved drugs for Metastatic Colorectal Cancer @ Drugs for Metastatic Colorectal Cancer Treatment- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Metastatic Colorectal Cancer Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Metastatic Colorectal Cancer Companies- Pfizer, Sanofi, Taiho Pharma, Ono Pharma, Hutchison Medipharma, Isofol Medical, Sumitomo Dainippon Pharma, G1 Therapeutics, Merck, AB Science, Pfizer, Daiichi Sankyo/Astrazeneca, Merck/Eisai, Mirati Therapeutics, Merck, Cardiff Oncology, and others.
• Metastatic Colorectal Cancer Pipeline Therapies- Adagrasib (MRTX849) + cetuximab, MK-4280A (favezelimab and pembrolizumab), Lynparza (olaparib) ± bevacizumab, Elunate (fruquintinib/HMPL-013), Corsela (trilaciclib), Lenvima (lenvatinib/MK-7902/E7080) + Keytruda (pembrolizumab), Modufolin (arfolitixorin), Lumakras (sotorasib) + Vectibix (panitumumab), Masitinib, Numidargistat (INCB001158), Enhertu (trastuzumab deruxtecan), Keytruda (pembrolizumab) + ibrutinib, Onvansertib, RRx-001, Lenvima (lenvatinib) + pembrolizumab, Tukysa (tucatinib) ± Herceptin (trastuzumab), NT-17/GX-I7 (efineptakin Alfa) + Keytruda (pembrolizumab), BDTX-189, Magrolimab + Erbitux (cetuximab), ONCOS-102 + IMFINZI (durvalumab), and others.
• Metastatic Colorectal Cancer Market Dynamics: Metastatic Colorectal Cancer Market Drivers and Barriers
• Metastatic Colorectal Cancer Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Metastatic Colorectal Cancer Drugs in development @ Metastatic Colorectal Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Key Insights
2. Metastatic Colorectal Cancer Market Report Introduction
3. Metastatic Colorectal Cancer Market Overview at a Glance
4. Metastatic Colorectal Cancer Epidemiology and Market Methodology
5. Metastatic Colorectal Cancer Executive Summary
6. Key Events
7. Disease Background and Overview
8. Metastatic Colorectal Cancer Epidemiology and Patient Population
9. Metastatic Colorectal Cancer Patient Journey
10. Metastatic Colorectal Cancer Marketed Therapies
11. Metastatic Colorectal Cancer Emerging Therapies
12. Metastatic Colorectal Cancer Market Analysis
13. Metastatic Colorectal Cancer KOL Views
14. Metastatic Colorectal Cancer SWOT Analysis
15. Metastatic Colorectal Cancer Unmet Needs
16. Metastatic Colorectal Cancer Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer

List of Top Selling Market Research Reports in 2025

ADHD Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Periodontal disease market- https://www.delveinsight.com/report-store/periodontal-disease-market
Surgical energy instruments Market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Surgical robotic system market- https://www.delveinsight.com/report-store/surgical-robotic-system-market
NK Cell Therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Vital sign monitors devices market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Thrombectomy devices market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Urea cycle disorders market- https://www.delveinsight.com/report-store/urea-cycle-disorders-market
Diabetic wound market- https://www.delveinsight.com/report-store/diabetic-wounds-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Positive airway pressure device market- https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
Thyroid cancer market- https://www.delveinsight.com/report-store/thyroid-cancer-market
LY3454738 drug insight- https://www.delveinsight.com/report-store/moderate-to-severe-atopic-dermatitis-pipeline-insight
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.